Heterogeneous Clearance Rates of Long-lived Lymphocytes Infected with HIV: Intrinsic Stability Predicts Lifelong Persistence

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Apr 10

PMID 12684537

Citations 127

Authors

M C Strain

H F Gunthard

D V Havlir

C C Ignacio

D M Smith

A J Leigh-Brown

T R Macaranas

R Y Lam

O A Daly

M Fischer

M Opravil

H Levine

L Bacheler

C A Spina

D D Richman

J K Wong

Affiliations

Soon will be listed here.

Abstract

Viral replication and latently infected cellular reservoirs persist in HIV-infected patients achieving undetectable plasma virus levels with potent antiretroviral therapy. We exploited a predictable drug resistance mutation in the HIV reverse transcriptase to label and track cells infected during defined intervals of treatment and to identify cells replenished by ongoing replication. Decay rates of subsets of latently HIV-infected cells paradoxically decreased with time since establishment, reflecting heterogeneous lymphocyte activation and clearance. Residual low-level replication can replenish cellular reservoirs; however, it does not account for prolonged clearance rates in patients without detectable viremia. In patients receiving potent antiretroviral therapy, the latent pool has a heterogeneous and dynamic composition that comprises a progressively increasing proportion of stable lymphocytes. Eradication will not be achieved with complete inhibition of viral replication alone.

Citing Articles

The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era.

Gutierrez H, Eugenin E NeuroImmune Pharm Ther. 2025; 3(3-4):211-219.

PMID: 39845128 PMC: 11751450. DOI: 10.1515/nipt-2024-0017.

HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond.

Zhang Y, Otte F, Stoeckle M, Thielen A, Daumer M, Kaiser R PLoS Pathog. 2024; 20(9):e1012526.

PMID: 39292732 PMC: 11410260. DOI: 10.1371/journal.ppat.1012526.

ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency.

Zhou M, Yang T, Yuan M, Li X, Deng J, Wu S J Virol. 2024; 98(8):e0003524.

PMID: 39082875 PMC: 11334468. DOI: 10.1128/jvi.00035-24.

Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.

Mdluli T, Slike B, Curtis D, Shubin Z, Tran U, Li Y Cell Rep. 2024; 43(6):114344.

PMID: 38850529 PMC: 11298786. DOI: 10.1016/j.celrep.2024.114344.

Ethnobotanical survey and phytochemistry of medicinal plants used in the management of HIV/AIDS in Eastern Uganda.

Owor R, Kawuma C, Nantale G, Kiyimba K, Obakiro S, Ouma S Heliyon. 2024; 10(11):e31908.

PMID: 38845918 PMC: 11153244. DOI: 10.1016/j.heliyon.2024.e31908.

References

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

Cavert W, Notermans D, Staskus K, Wietgrefe S, Zupancic M, GEBHARD K . Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997; 276(5314):960-4. DOI: 10.1126/science.276.5314.960. View

Pitcher C, Hagen S, Walker J, Lum R, Mitchell B, Maino V . Development and homeostasis of T cell memory in rhesus macaque. J Immunol. 2001; 168(1):29-43. DOI: 10.4049/jimmunol.168.1.29. View

Brooks D, Kitchen S, Kitchen C, Zack J . Generation of HIV latency during thymopoiesis. Nat Med. 2001; 7(4):459-64. DOI: 10.1038/86531. View

Foudraine N, Hoetelmans R, Lange J, de Wolf F, van Benthem B, Maas J . Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet. 1999; 351(9115):1547-51. DOI: 10.1016/S0140-6736(98)07333-4. View

Dornadula G, Zhang H, VanUitert B, Stern J, Livornese Jr L, Ingerman M . Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999; 282(17):1627-32. DOI: 10.1001/jama.282.17.1627. View

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S . Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999; 340(21):1605-13. DOI: 10.1056/NEJM199905273402101. View

Perelson A, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K . Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997; 387(6629):188-91. DOI: 10.1038/387188a0. View

Cone R, Gowland P, Opravil M, Grob P, Ledergerber B . Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study. AIDS. 1998; 12(17):2253-60. DOI: 10.1097/00002030-199817000-00005. View

10.

Holte S, Melvin A, Mullins J, Tobin N, Frenkel L . Density-dependent decay in HIV-1 dynamics. J Acquir Immune Defic Syndr. 2006; 41(3):266-76. DOI: 10.1097/01.qai.0000199233.69457.e4. View

11.

Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P . Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995; 171(6):1411-9. DOI: 10.1093/infdis/171.6.1411. View

12.

Blankson J, Finzi D, Pierson T, Sabundayo B, Chadwick K, Margolick J . Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000; 182(6):1636-42. DOI: 10.1086/317615. View

13.

Neumann A, Tubiana R, Calvez V, Robert C, Li T, Agut H . HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 1999; 13(6):677-83. DOI: 10.1097/00002030-199904160-00008. View

14.

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

15.

Taylor S, van Heeswijk R, Hoetelmans R, Workman J, Drake S, White D . Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS. 2000; 14(13):1979-84. DOI: 10.1097/00002030-200009080-00014. View

16.

Zack J, Arrigo S, Weitsman S, Go A, Haislip A, Chen I . HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990; 61(2):213-22. DOI: 10.1016/0092-8674(90)90802-l. View

17.

Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373(6510):123-6. DOI: 10.1038/373123a0. View

18.

Chun T, Engel D, Mizell S, Ehler L, Fauci A . Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998; 188(1):83-91. PMC: 2525548. DOI: 10.1084/jem.188.1.83. View

19.

Kulkosky J, Culnan D, Roman J, Dornadula G, Schnell M, Boyd M . Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001; 98(10):3006-15. DOI: 10.1182/blood.v98.10.3006. View

20.

Furtado M, Callaway D, Phair J, Kunstman K, Stanton J, Macken C . Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999; 340(21):1614-22. DOI: 10.1056/NEJM199905273402102. View